Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic ex-vivo-treated peripheral blood mononuclear cells

A preparation of allogeneic peripheral blood mononuclear cells (PBMCs) treated and induced ex vivo to undergo early apoptosis, with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic ex-vivo-treated PBMCs, the early apoptotic cells are engulfed by macrophages and immature dendritic cells (DCs). This leads to immune modulation, which may result in immune-mediated tumor cell death.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic ex-vivo-treated PBMCs
US brand name:	Allocetra-OTS

allogeneic ex-vivo-treated peripheral blood mononuclear cells

Search NCI's Drug Dictionary